Soliqua
Manufacturing · United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.soliqua100-33.comRevenue
$33.8 MillionIndustry
About Soliqua
Is Soliqua your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Soliqua has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Soliqua launches new products
Check if Soliqua has recently received funding, and reach out quickly before it becomes old news!
Click to see if Soliqua had a recent Job posting/layoffs
Soliqua, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Soliqua
Check out if Soliqua is spiking on competitors!
Earning: See what the market has to say on Soliqua recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Soliqua as Masked Content
Find 3 more new buyers
Compare Similar Companies to Soliqua
Compare insights from companies similar to Soliqua, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Soliqua is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Soliqua is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Soliqua.
Soliqua Tech Stack
A closer look at the technologies used by Soliqua
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Soliqua
SOLIQUA 100/33 is a once-daily injectable prescription medication that combines the long-acting insulin analog insulin glargine and the GLP-1 receptor agonist lixisenatide. Used alongside diet and exercise in adults with type 2 diabetes mellitus, it targets multiple pathways to help improve blood sugar control when other therapies have not achieved... Read More